Drugs /

asparaginase

Back to Drugs List

Overview

NCI Definition [1]:
An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.

Clinical Trials

View Clinical Trials for asparaginase

Asparaginase has been investigated in 7 clinical trials, of which 5 are open and 2 are closed. Of the trials investigating asparaginase, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open).

KMT2A Fusion, CBFB-MYH11 Fusion, and RUNX1-RUNX1T1 Fusion are the most frequent biomarker inclusion criteria for asparaginase clinical trials.

Acute lymphoblastic leukemia, acute myeloid leukemia, and lymphoblastic lymphoma are the most common diseases being investigated in asparaginase clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Asparaginase
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Asparaginase
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating asparaginase and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
colaspase, l-asnase, asnase, l-asp, leunase, asparaginase [chemical/ingredient], l-asparaginase, crisantaspase, 290, l-asparaginase preparation, crasnitine, escherichia coli asparaginase (substance), mk-965, l-asparaginase, l-asparagine amidohydrolase, asparaginase ii, asparaginase, serasa, asparagine deaminase, 109229, escherichia coli asparaginase ii, paronal, asparaginase (substance), kidrolase, leucogen, asn-ase, l-asparagine amidohydrolase, l asparagine amidohydrolase, asparaginase ii, asparaginase, escherichia coli asparaginase, a-ase, asparaginase (e. coli), laspar, deaminase, asparagine, asparaginase preparation, l-asparaginase preparation (product), asparaginase-e.coli, l-asparagine amidohydrolase, elspar, 106977, putative l-asparaginase precursor, lcf-asp, re-82-tad-15, asp-1, ec 3.5.1.1
NCIT ID [1]:
C286
SNOMED ID [1]:
C-78275

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.